Raymond James Financial
XGN icon

Raymond James Financial’s Exagen XGN Stock Holding History

Raymond James Financial’s Portfolio XGN Stock Details XGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,568
Closed -$10.9K – 6809
2025
Q2 		$10.9K Buy
+1,568
New +$9.53K ﹤0.01% 5890

Other funds holding XGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Raymond James Financial's XGN Position: Q3 2025 in Review

Raymond James Financial sold out of Exagen (XGN) in Q3 2025, closing a stake of 1,568 shares — an estimated $10.9K sold.

Raymond James Financial first reported a position in XGN in Q2 2025 and held it in 1 quarter. The position peaked at $10.9K in Q2 2025. 62 funds tracked by Wall St. Rank hold XGN as of Q3 2025.

  • Raymond James Financial reported no remaining Exagen position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 1,568 Exagen shares in Q3 2025, an estimated $10.9K.
  • Raymond James Financial first reported a position in Exagen in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Exagen position peaked at $10.9K in Q2 2025.
  • 62 funds tracked by Wall St. Rank held Exagen as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.